Clinical significance of prostate cancer identified by transperineal standard template biopsy in men with nonsuspicious multiparametric magnetic resonance imaging

被引:0
|
作者
Dahl, Douglas M. [1 ]
Wu, Shulin [1 ,2 ]
Lin, Sharron X. [1 ]
Hu, Mengjie [2 ]
Barney, Alfred A. [1 ]
Kim, Michelle M. [1 ]
Cornejo, Kristine M. [2 ]
Harisinghani, Mukesh G. [3 ]
Feldman, Adam S. [1 ]
Wu, Chin -Lee [1 ,2 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Dept Urol, Boston, MA 02115 USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA
关键词
MRI; ACCURACY; PROMIS;
D O I
10.1016/j.urolonc.2023.11.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Multiparametric magnetic resonance imaging (mpMRI) of the prostate has excellent sensitivity in detecting clinically significant prostate cancer (csCaP). However, whether a negative mpMRI in patients with a clinical suspicion of CaP can omit a confirmatory biopsy remains less understood and without consensus. Transperineal (TP) standard template biopsy (SBx) provides an effective approach to CaP detection. Our aim is to provide a comprehensive understanding of the CaP characteristics detected through TP SBx that are systematically overlooked by mpMRI. Methods: We conducted a retrospective analysis of all men who underwent prebiopsy mpMRI and subsequent a 20-core TP SBx at our hospital from September 2019 to February 2021. Patients with suspicious mpMRI received a combined TP SBx and targeted biopsy (TBx) (suspicious group), while those without suspicious (negative) mpMRI and who proceeded to biopsy, received TP SBx only (nonsuspicious group). A negative mpMRI was defined as the absence of suspicious findings and/or the presence of low-risk areas with a PI-RADS score of <= 2. Subsequently, we compared and evaluated the clinical and biopsy characteristics between these 2 groups. Results: We identified 301 men in suspicious group and 215 men in nonsuspicious group. The overall CaP detection rate and csCaP detection rate by TP SBx were 74.1%, 38.9% for suspicious group and 43.3%, 14.9% for nonsuspicious group, respectively. csCaP NPV of mpMRI was 85.1% with a csCaP prevalence 28.9%. The greatest percentage of cancer involvement (GPC) in biopsy core from nonsuspicious group was significantly lower than those of suspicious group (40% vs. 50%, p = 0.005), In multivariate logistic analysis, only PSAD > 0.15 ng/ml/cc was identified as an independent and significant predictor of csCaP in nonsuspicious group. Conclusion: Within our cohort, false-negative rates of mpMRI for csCaP are substantial, reaching 15%. Nonsuspicious cases may contain a large volume tumor since the high GPC of SBx. For cases with nonsuspicious imaging and higher PSAD, a confirmatory biopsy may be necessary due to the increased risk of missed csCaP by mpMRI. (c) 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:28e21 / 28e28
页数:8
相关论文
共 50 条
  • [41] Multiparametric magnetic resonance imaging/ultrasound fusion targeted and systematic transperineal prostate biopsies for prostate cancer diagnosis
    Galea, L. A.
    Frentescu, F.
    Tan, A.
    HISTOPATHOLOGY, 2022, 81 : 188 - 188
  • [42] The Optimal Prostate Biopsy in the Era of Multiparametric Magnetic Resonance Imaging
    Smigelski, Michael
    Taneja, Samir S.
    EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (01): : 56 - 57
  • [43] Multiparametric magnetic resonance imaging predicts the presence of prostate cancer in patients with negative prostate biopsy
    Lista, F.
    Castillo, E.
    Gimbernat, H.
    Rodriguez-Barbero, J. M.
    Panizo, J.
    Angulo, J. C.
    ACTAS UROLOGICAS ESPANOLAS, 2015, 39 (02): : 85 - 91
  • [44] Should transperineal template biopsy become the new standard for prostate cancer diagnosis?
    Moran, D.
    McGarvey, C.
    Lynch, T.
    Hegarty, N.
    O'Malley, K.
    BJU INTERNATIONAL, 2014, 114 : 23 - 23
  • [45] Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer
    Stabile, Armando
    Dell'Oglio, Paolo
    Soligo, Matteo
    De Cobelli, Francesco
    Gandaglia, Giorgio
    Fossati, Nicola
    Esposito, Antonio
    Brembilla, Giorgio
    Karnes, R. Jeffrey
    Montorsi, Francesco
    Briganti, Alberto
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (04): : 594 - 600
  • [46] Multiparametric magnetic resonance imaging and follow-up to avoid prostate biopsy in 4259 men
    Venderink, Wulphert
    van Luijtelaar, Annemarijke
    van der Leest, Marloes
    Barentsz, Jelle O.
    Jenniskens, Sjoerd F. M.
    Sedelaar, Michiel J. P.
    Hulsbergen-van de Kaa, Christina
    Overduin, Christiaan G.
    Fuetterer, Jurgen J.
    BJU INTERNATIONAL, 2019, 124 (05) : 775 - 784
  • [47] Managing Discordant Findings Between Multiparametric Magnetic Resonance Imaging and Transrectal Magnetic Resonance Imaging-directed Prostate Biopsy-The Key Role of Magnetic Resonance Imaging-directed Transperineal Biopsy
    Bajeot, Anne-Sophie
    Covin, Bertrand
    Meyrignac, Oliver
    Pericart, Sarah
    Aziza, Richard
    Portalez, Daniel
    Graff-Cailleaud, Pierre
    Ploussard, Guillaume
    Roumiguie, Mathieu
    Malavaud, Bernard
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (03): : 296 - 303
  • [48] MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy
    Huang, Cong
    Song, Gang
    Wang, He
    Ji, Guangjie
    Li, Jie
    Chen, Yuke
    Fan, Yu
    Fang, Dong
    Xiong, Gengyan
    Xin, Zhongcheng
    Zhou, Liqun
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [49] Re: Comparative Analysis of Transperineal Template Saturation Prostate Biopsy Versus Magnetic Resonance Imaging Targeted Biopsy with Magnetic Resonance Imaging-Ultrasound Fusion Guidance
    Lazzeri, Massimo
    Lughezzani, Giovanni
    Guazzoni, Giorgio
    EUROPEAN UROLOGY, 2015, 68 (03) : 535 - 536
  • [50] Clinical significance of perineural invasion by prostate cancer on magnetic resonance imaging-targeted biopsy
    Suresh, Nivedita
    Teramoto, Yuki
    Goto, Takuro
    Wang, Ying
    Miyamoto, Hiroshi
    HUMAN PATHOLOGY, 2022, 121 : 65 - 72